drugset / Trial / NCT00019331

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331

Treatment

Summary

RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 and/or sargramostim in treating adults who have metastatic solid tumors.

Timeline

Start
1997-10
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Subject ras peptide cancer vaccine Vaccine Subcutaneous
Subject sargramostim Protein / enzyme biologic Subcutaneous
Background DetoxPC Unknown Subcutaneous